Genetic polymorphism of the drug-metabolizing enzyme Cytochrome P4502E1 (CYP2E1) in a healthy Saudi population

ObjectivesCytochrome P450 2E1 (CYP2E1) is one of the major enzymes involved in the metabolism and detoxification of various drugs and xenobiotics. Polymorphisms in the CYP2E1 gene exhibit high inter-individual variations associated with alterations in CYP2E1 gene expression and enzyme function. This study aimed to determine the genotype distributions and allele frequencies of CYP2E1*1B, *5B, and *6 polymorphisms among Saudis in western Saudi Arabia.MethodsIn total, 140 healthy Saudis attending King Abdulaziz University Hospital between February and April 2021 were included in the study. CYP2E1 gene polymorphisms were determined by polymerase chain reaction-restriction fragment length polymorphism analysis.ResultsThe genotype frequencies of CYP2E1*1B A2A2, A2A1, and A1A1 were 54.29%, 40%, and 8%, respectively. The frequencies of CYP2E1*5B c1c1 and c1c2 genotypes were approximately 99.93% and 0.07%, respectively. The frequencies of the CYP2E1*6 DD, DC, and CC genotypes were 91.43%, 7.85%, and 0.72%, respectively. The genotype distributions for these polymorphisms were consistent with the expected distribution based on Hardy-Weinberg equilibrium. The allele frequencies were 74.29% A2 and 25.71% A1 for CYP2E1*1B, 99.64% c1 and 0.36% c2 for CYP2E1*5B, and 95.36% D and 4.65% C for CYP2E1*6.ConclusionThe genotype distribution of CYP2E1*1B polymorphism was higher in the western Saudi population, whereas the CYP2E1*5B and *6 polymorphisms were lower than the global average. Knowledge of the prevalence of CYP2E1 polymorphisms among our population will provide a better understanding of whether individual patients might benefit from their medication or whether they might develop adverse effects.     

细胞色素P450 2D6等位基因CYP2D6C的特异扩增法测定

细胞色素Ｐ４５０２Ｄ６（ＣＹＰ２Ｄ６）第２７０３－５位ＡＡＧ缺失造成表达产物第２８１位赖氨酸缺失的等位基因称为ＣＹＰ２Ｄ６Ｃ．利用等位基因特异扩增法（ＡＳＡ）原理,建立了ＡＳＡ－ＰＣＲ测定ＣＹＰ２Ｄ６的方法．经３９６例测定,说明本法快捷,污染少．测定结果显示ＣＹＰ２Ｄ６Ｃ不属于ＣＹＰ２Ｄ６酶缺陷等位基因,表型仍为快代谢．     

人肝细胞色素P450 2C8/9、2E1比活性测定

目的　建立甲苯磺丁脲羟化酶 (CYP2C8/ 9)和氯羟苯口恶唑 6 羟化酶 (CYP2E1)比活性的测定方法 ,为深入研究CYP45 0在药物代谢中的作用奠定基础。方法　从成人肝细胞中提取微粒体 ,测定其蛋白含量 ,以甲苯磺丁脲、氯羟苯口恶唑为底物 ,用HPLC以梯度洗脱法测定其代谢产物羟基甲苯磺丁脲及 6 羟基氯羟苯 口恶唑生成量 ,据此计算人肝细胞色素P45 0 (CYP45 0 )同工酶甲苯磺丁脲羟化酶 (CYP2C8/9)和氯羟苯 口恶唑 6 羟化酶 (CYP2E1)比活性。结果　于不同时间反复测定的CYP2C8/ 9、CYP2E1比活性无差异。结论　CYP2C8/ 9、CYP2E1的测定方法较为简单、稳定、重复性好 ,可用于新药筛选、安全性评价及肝脏病理学、毒理学研究。     

人肝细胞色素P450 2C8/9、2E1比活性测定

目的　建立甲苯磺丁脲羟化酶 (CYP2C8/ 9)和氯羟苯口恶唑 6 羟化酶 (CYP2E1)比活性的测定方法 ,为深入研究CYP45 0在药物代谢中的作用奠定基础。方法　从成人肝细胞中提取微粒体 ,测定其蛋白含量 ,以甲苯磺丁脲、氯羟苯口恶唑为底物 ,用HPLC以梯度洗脱法测定其代谢产物羟基甲苯磺丁脲及 6 羟基氯羟苯 口恶唑生成量 ,据此计算人肝细胞色素P45 0 (CYP45 0 )同工酶甲苯磺丁脲羟化酶 (CYP2C8/9)和氯羟苯 口恶唑 6 羟化酶 (CYP2E1)比活性。结果　于不同时间反复测定的CYP2C8/ 9、CYP2E1比活性无差异。结论　CYP2C8/ 9、CYP2E1的测定方法较为简单、稳定、重复性好 ,可用于新药筛选、安全性评价及肝脏病理学、毒理学研究。     

人肝细胞色素P450 2C8/9、2E1比活性测定

目的建立甲苯磺丁脲羟化酶(CYP2C8/9)和氯羟苯口恶唑6-羟化酶(CYP2E1)比活性的测定方法,为深入研究CYP450在药物代谢中的作用奠定基础.方法从成人肝细胞中提取微粒体,测定其蛋白含量,以甲苯磺丁脲、氯羟苯口恶唑为底物,用HPLC以梯度洗脱法测定其代谢产物羟基甲苯磺丁脲及6-羟基氯羟苯口恶唑生成量,据此计算人肝细胞色素P450(CYP450)同工酶甲苯磺丁脲羟化酶(CYP2C8/9)和氯羟苯口恶唑6-羟化酶(CYP2E1)比活性.结果于不同时间反复测定的CYP2C8/9、CYP2E1比活性无差异.结论 CYP2C8/9、CYP2E1的测定方法较为简单、稳定、重复性好,可用于新药筛选、安全性评价及肝脏病理学、毒理学研究.     

草甘膦对大鼠细胞色素P450 2B1和P450 2C11基因表达的影响

采用酶学和分子生物学方法，研究了两种草甘膦除草剂对大鼠细胞色素Ｐ４５０２Ｂ１和２Ｃ１１（ＣＹＰ４５０２Ｂ１和２Ｃ１１）ｍＲＮＡ表达的影响以探讨其作用机理。结果表明，草甘膦Ⅱ可增加肝细胞中ＣＹＰ４５０２Ｂ１ｍＲＮＡ转录水平，与对照组比较有显著性差异（Ｐ＜０．０５）；而草甘膦Ⅰ对肝细胞ＣＹＰ４５０２Ｂ１ｍＲＮＡ没有明显影响（Ｐ＞０．０５）。两种草甘膦均可显著降低肾脏ＣＹＰ４５０２Ｂ１ｍＲＮＡ表达水平，与对照组比较均有极显著差异（Ｐ＜０．０１）。草甘膦Ⅰ可使大鼠肝细胞中ＣＹＰ４５０２Ｃ１１ｍＲＮＡ转录水平显著降低，与对照组比较有显著性差异（Ｐ＜０．０５）；而草甘膦Ⅱ对大鼠肝细胞中ＣＹＰ４５０２Ｃ１１ｍＲＮＡ没有明显影响。     

Stereoselective bupropion hydroxylation as an in vivo phenotypic probe for cytochrome P4502B6 (CYP2B6) activity

The clearance of racemic bupropion, metabolized selectively by CYP2B6 in vitro, has been used clinically to phenotype CYP2B6 activity, polymorphisms, and drug interactions but has known limitations. Bupropion hydroxylation by CYP2B6 is stereoselective. This investigation assessed the stereoselectivity of bupropion pharmacokinetics and the influence of CYP2B6 induction. Ten healthy volunteers received immediate-release bupropion before and after 7 days of rifampin. Plasma and urine bupropion and hydroxybupropion were analyzed using a stereoselective assay. Plasma area under the curve (AUC(0-infinity)) and maximum concentrations were 3-fold greater for R- than S-bupropion. Bupropion apparent oral clearance was 3- and 2-fold greater for S- than R- and R,S-bupropion, respectively. Hydroxybupropion plasma AUC(0-infinity) and elimination half-life were significantly less for (S,S)- than (R,R)- and the racemate. (S,S)-hydroxybupropion was formation rate limited, whereas (R,R)-hydroxybupropion and the racemate were elimination rate limited. Rifampin doubled both R- and S-bupropion clearance and caused 4-fold increases in both (R,R)- and (S,S)-hydroxybupropion formation clearances. Increases in the plasma hydroxybupropion/bupropion AUC(0-infinity) ratio were greater for (S,S)- than (R,R)-hydroxybupropion. Simplified plasma and urine metrics of stereoselective bupropion metabolism and clearance were identified. Because metabolite formation clearance is the best in vivo metric of enzyme activity and due, therefore, to faster S-bupropion elimination and formation rate-limited (S,S)-hydroxybupropion kinetics, stereoselective S-bupropion hydroxylation and (S,S)-hydroxybupropion formation clearance may be a useful and improved phenotypic probe for CYP2B6.     

Covalent binding and inhibition of cytochrome P4502E1 by trichloroethylene

1. To investigate the effects of trichloroethylene on cytochrome P4502E1 (CYP2E1), an isozyme responsible for its metabolic activation, mice were treated with trichloroethylene and Western blot staining with both anti-dichloroacetyl and anti-CYP2E1 antisera detected acomigrating 50 kDaprotein band. There was adose-dependent increase in the intensity of the 50 kDa protein adduct stained immunochemically with antidichloroacetyl. 2. CYP2E1 enzyme activity was decreased from control levels in a dose-dependent manner in mice treated with 250-500?mg kg TRI. 3. Microsomal incubations with trichloroethylene resulted in covalent binding to several proteins including a 50 kDa adduct, which is in contrast with the selective binding to the 50 kDa protein observed in vivo. 4. CYP2E1 enzyme activity levels were significantly decreased following microsomal incubation with NADPH and trichloroethylene, and additionally there was a time- and NADPH- dependent decrease in enzyme activity indicating that trichloroethylene is a mechanism- based inhibitor of CYP2E1.     

Development of rapid genotyping methods for single nucleotide polymorphisms of cytochrome P450 2C9 (CYP2C9) and cytochrome P450 2C19 (CYP2C19) and their clinical application in pediatric patients with epilepsy

Genetic polymorphism of cytochrome P450 2C9 (CYP2C9) and cytochrome P450 2C19 (CYP2C19) is widely known to contribute to interindividual differences in the pharmacokinetics of some antiepileptic drugs. We developed a rapid detection assay of polymorphisms of CYP2C9 and CYP2C19, using the Light Cycler(?) polymerase chain reaction (PCR) system. Using this assay, we examined polymorphisms in 20 Japanese pediatric patients prescribed phenytoin for the treatment of epilepsy, and classified their polymorphisms into four groups: group I, CYP2C9*1/*1 and CYP2C19*1/*1; group II, CYP2C9*1/*1 and CYP2C19*1/*2 or *1/*3; group III, CYP2C9*1/*1 and CYP2C19*2/*2; and group IV, CYP2C9*1/*3 and CYP2C19*1/*2 or *1/*3. The mean maximal elimination rates (V(max)) in groups I, II, III and IV were 13.1, 11.2, 10.2 and 8.0 mg/day/kg, respectively, with statistically significant differences among groups (p=0.012, Kruskal-Wallis analysis). The intrinsic metabolic activity (V(max)/K(m)) of groups I, II, III and IV were 2.9, 2.2, 1.5 and 1.1 l/day/kg, respectively (p=0.009), again with significant differences among groups. These findings indicate that polymorphism of CYP2C9 and CYP2C19 plays an important role in phenytoin metabolism in children. With a total processing time for this assay of less than 3 hours, prediction of the optimal phenytoin dosage based on the CYP2C9 and CYP2C19 genotypes will be possible before commencement of therapy, resulting in the prevention of phenytoin overdoses in pediatric patients with epilepsy.     

Interference with growth hormone stimulation of hepatic cytochrome P4502C11 expression in hypophysectomized male rats by 3-methylcholanthrene

Cytochrome P450 2C11 (CYP2C11) is a sexually dimorphic liver enzyme whose expression is regulated by the male pulsatile pattern of growth hormone (GH) secretion. Hepatic CYP2C11 expression is down-regulated by polycyclic aromatic hydrocarbons such as 3-methylcholanthrene (MC). An attractive hypothesis as to the mechanism of CYP2C11 down-regulation by aromatic hydrocarbons is the disruption of normal GH signaling by exposure to these compounds. To evaluate the effects of MC on the ability of GH to stimulate hepatic CYP2C11 expression, our approach was to employ GH replacement in male Fischer 344 rats made GH-deficient by hypophysectomy (hypx). Groups of hypx rats received the following treatments: vehicle; GH alone (twice daily, 125 microg/kg sc, days 1-6); MC alone (20 mg/kg gavage, days 1, 3, and 5); and both GH and MC. Rats were euthanized on day 7. As a positive control response, pronounced induction of hepatic CYP1A1 apoprotein was observed in all MC-treated rats. CYP2C11 expression in hypx rats receiving GH alone was increased at the mRNA, apoprotein, and catalytic activity (testosterone 16alpha-hydroxylation) levels, with mRNA and apoprotein levels approaching that of intact male rats. The inability of GH to fully restore CYP2C11 catalytic activity was attributed to the lowered NADPH-cytochrome P450 reductase apoprotein and catalytic activity observed in all hypx rats. CYP2C11 expression in hypx rats receiving both GH and MC was significantly lower at the mRNA, apoprotein, and catalytic activity levels than that observed in hypx rats treated with GH alone, but significantly higher at the mRNA, apoprotein, and catalytic activity levels than that observed in vehicle-treated hypx rats and in hypx rats treated with MC alone. These data suggest that MC interferes with the ability of GH to stimulate CYP2C11 expression. Thus, disruption of GH signaling by aromatic hydrocarbons may represent a mechanism contributing to the suppression of CYP2C11 gene expression.     

An interaction between the cytochrome P450 probe substrates chlorzoxazone (CYP2E1) and midazolam (CYP3A)

AIMS: The use of multiple probe substrates to evaluate the activity of drug metabolizing enzymes requires that there are no inter-substrate interactions. As part of a series of studies to develop a clinically useful collection of probe substrates that could be given alone or in any combination, we observed an interaction between midazolam (MDZ) and another component of the six-drug cocktail. Published data indicated that the interacting component was likely to be chlorzoxazone. This was investigated as part of a second study. The data relating to the interaction from both studies are reported here. METHODS: Both studies were performed in 16 healthy subjects. All treatments were given orally after an overnight fast. In study 1, which was performed to a four-period, open, crossover design, subjects received on separate occasions MDZ 5 mg, diclofenac 25 mg, a four drug cocktail (caffeine 100 mg, mephenytoin 100 mg, debrisoquine 10 mg and chlorzoxazone 250 mg) and a six drug cocktail (caffeine 100 mg, mephenytoin 100 mg, debrisoquine 10 mg, chlorzoxazone 250 mg, diclofenac 25 mg and MDZ 5 mg). In study 2, which was performed to a two-period, open, crossover design, subjects received a five drug cocktail (as the six drug cocktail in the first study, but without chlorzoxazone and with diclofenac dose increased to 50 mg) and a six drug cocktail (as five drug cocktail, with chlorzoxazone 250 mg). In both studies, blood samples were taken for measurement of plasma MDZ and 1-hydroxy MDZ (1-OH MDZ) concentrations. In study 1, blood samples were taken up to 12 h post-dose while in study 2 a single sample was taken 2 h after dosing. In study 1, the potential interaction between MDZ and the other components of the six drug cocktail was assessed by comparing AUClast ratios (1-OH MDZ/MDZ) between the two treatments. Additionally, a single sampling timepoint of 2 h post-dose for determination of concentration, rather than AUC, ratios was established. The 2 h plasma concentration ratios from studies 1 and 2 were combined and a pooled analysis performed to compare ratios within each study (to determine the change in ratio when MDZ was dosed with and without chlorzoxazone) and between studies (to determine the consistency of the ratios when MDZ was given either as part of the two six drug cocktails or when given alone and as part of the five drug cocktail). RESULTS: In study 1, both the AUClast ratio and the 2 h post-dose plasma concentration ratio were reduced when MDZ was given as part of the six drug cocktail in comparison with those for MDZ alone. This was the result of an increase in MDZ, rather than decrease in 1-OH MDZ, concentrations and was considered to result from a reduction in first pass metabolism of MDZ. The geometric mean AUClast values (with 95% CI) for MDZ were 95.6 (79.0, 115.7) and 160.4 (133.6, 192.6) microg l(-1) h when given alone and as part of the six drug cocktail, respectively. The corresponding values for 1-OH MDZ were 789.6 (697.6, 893.6) and 791.4 (701.7, 892.6) microg l(-1) h. The ratio of adjusted geometric mean AUClast ratios for the two treatments was 1.82 (90% CI 1.48, 2.23, P < 0.001). The pooled plasma 1-OH MDZ/MDZ ratio data from both studies showed that the differences in MDZ metabolism observed in study 1 were replicated in study 2. The adjusted geometric mean 1-OH MDZ/MDZ ratios when MDZ was given alone and as part of the six drug cocktail were 7.79 and 4.59, respectively, for study 1 (ratio 1.70, 95% CI 1.36, 2.11, P < 0.001) and 7.64 and 4.60 for study 2 (ratio 1.66, 95% CI 1.34, 2.06, P < 0.001). These data indicate that when given orally chlorzoxazone interacts with MDZ, increasing plasma MDZ concentrations. In contrast, there was no difference between the plasma 1-OH MDZ/MDZ ratios when MDZ was given alone and as part of the five drug cocktail indicating that there were no interactions between MDZ and any of the other components of that cocktail. CONCLUSIONS: Chlorzoxazone appears to significantly influence the pharmacokinetics of oral MDZ, probably through inhibition of first pass metabolism by CYP3A in the GI tract. Data from these studies and literature evidence showing a further interaction between chlorzoxazone and CYP1A2 substrates and questions concerning the specificity of chlorzoxazone as a probe substrate for CYP2E1, indicate that the use of chlorzoxazone in multisubstrate probe cocktails should be avoided.     

Mitochondrial dysfunction by gamma-irradiation accompanies the induction of cytochrome P450 2E1 (CYP2E1) in rat liver

Multiple biological effects are induced by ionizing radiation through dysfunction of cellular organelles, direct interaction with nucleic acids and production of free radical species. The expression of cytochrome P450s was assessed in the livers of 60Co gamma-irradiated rats. Three gray (G) of gamma-irradiation caused CYP2E1 induction with a 3.6-fold increase in the mRNA at 24 h, whereas the expression of CYP1A2 and CYP3A was not changed. Pharmacokinetics of chlorzoxazone, a specific substrate of CYP2E1, was studied in 3 G-irradiated rats. The area under the plasma concentration-time curve from time zero to infinity of 6-hydroxychlorzoxazone and the amount of 6-hydroxychlorzoxazone excreted in 8 h urine were both significantly greater than those in control rats. Hepatic CYP2E1 was not induced in rats exposed to 0.5-1 G of gamma-rays. Rats irradiated at 6-9 G accumulated doses of gamma-rays exhibited smaller increases in the mRNA due to liver injury than those irradiated at a single dose of 3 G gamma-rays. The plasma glucose and insulin levels were not altered in rats with 3 G of gamma-irradiation. As the exposure level of gamma-irradiation increased, the activity of hepatic aconitase, a key enzyme in energy metabolism in mitochondria, was 30-90% decreased. The amount of mitochondrial DNA per gram of wet liver was 50% decreased in rats exposed to 3 G of gamma-rays. These results demonstrated that gamma-ray irradiation at the exposure level inducing organelle dysfunction induced CYP2E1 in the liver, which might be associated with mitochondrial damage, but not with alterations in glucose or insulin levels.     

Piperine effects on the expression of P4502E1, P4502B and P4501A in rat

Treatment of rat with piperine (PIP) (1·4 mmol/kg, 3 days ip injections) resulted in an approximate two-fold increase in total liver microsomal P450 content relative to that in uninduced animals.

2. 4-Nitrophenol and aniline hyroxylase activities in the hepatic microsomes prepared from rat treated with PIP decreased by 30 and 28% respectively as compared with control. Immunoblot analyses also revealed decreased P4502E1 levels in hepatic microsomes from PIP-treated animals.

3. In contrast with P4502E1 suppression, hepatic 2B1 and 2B2 levels were significantly increased in PIP-induced animals, as evidenced by both metabolic activity and immunoblot analysis of the liver microsomal fractions. The rate of hexobarbital hydroxylase activity in microsomes from PIP-treated animals was markedly elevated and was inhibited by approximately 62% in the presence of monoclonal anti-P4502B IgG. Immunoblot analyses demonstrated that P4502B1 ana 2B2 levels in hepatic microsomes from PIP-treated animals were comparable with those from phenobarbital-treated animals.

4. 7-Ethoxycoumarin deethylase activity was elevated approximately two-fold in PIP-induced animals and was 17% of that derived from 3-methylcholanthrene-induced animals. 7-ethoxycoumarin deethylase activity in PIP-induced hepatic microsomes was inhibited 63% in the presence of monoclonal anti-P4501 A antibody. Immunoblot analysis confirmed the increase in P4501A levels by PIP, which was 15% of that in hepatic microsomes from 3-methylcholanthrene-induced animals.

5. PIP treatment failed to affect microsomal epoxide hydrolase (mEH) and glutathione S-transferases (GST) expression, as indicated by immunoblot analyses using polyclonal antibodies toward mEH and GST subunits Ya, Yb1, Yb2 and Yc.

6. These results demonstrate that PIP treatment suppressed P4502E1 expression and enhanced 2B and 1A expression, whereas this agent failed to affect hepatic mEH and GST expression.     

Effect of eurycomanone on cytochrome P450 isoforms CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2E1 and CYP3A4 in vitro

Eurycomanone, an active constituent isolated from Eurycoma longifolia Jack, was examined for modulatory effects on cytochrome P450 (CYP) isoforms CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2E1 and CYP3A4 using in vitro assays. The IC₅₀ value was determined to assess the potencies of modulation for each CYP isoform. Our results indicated that eurycomanone did not potently inhibit any of the CYP isoforms investigated, with IC₅₀ values greater than 250 μg/ml. Hence there appears to be little likelihood of drug–herb interaction between eurycomanone or herbal products with high content of this compound and CYP drug substrates via CYP inhibition.     

Hormonal regulation of the mRNA level of male-dominant cytochrome P450 (CYP2C27) in hamster livers

Hormonal regulation in the expression of CYP2C27, a male-predominant form of cytochrome P450 in the hamster, was investigated. The mRNA level of CYP2C27 was five-fold higher in male than in female livers. The mRNA level was suppressed by both gonadectomy and hypophysectomy in male, while the mRNA level was increased by the same treatment in female, resulting in the disappearance of sex difference. In both sexes, treatment of the gonadectomized animals with testosterone induced the cytochrome over the level of shamoperated males. Treatment of the hypophysectomized animals with testosterone elevated the level in females. On the other hand, oestradiol did not show any effects on either the gonadectomized or the hypophysectomized animals of both sexes. Twice-daily injection of growth hormone to hypophysectomized animals restored the level in males. Continuous infusion of growth hormone to hypophysectomized animals suppressed the level in both sexes. These results indicate that the expression of CYP2C27 in hamsters is under the control of endocrine factors and suggest that the gonadal-pituitary axis pathway is a control mechanism as proposed in rats and mice.